These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3457672)

  • 1. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activity of cefotetan against anaerobic bacteria].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):643-4. PubMed ID: 2877431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of cefotetan against anaerobic bacteria.
    Watt B; Brown FV
    J Antimicrob Chemother; 1985 Jun; 15(6):671-7. PubMed ID: 3861604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefbuperazone, a new cephamycin, against anaerobic bacteria.
    Prabhala RH; Thadepalli H; Rao B; Bansal MB; Marshall R
    Antimicrob Agents Chemother; 1985 Apr; 27(4):640-2. PubMed ID: 4004195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Feb; 27(2):162-6. PubMed ID: 3985600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Apr; 32(4):601-4. PubMed ID: 3163908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cefmetazole against anaerobic bacteria.
    Cornick NA; Jacobus NV; Gorbach SL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):2010-2. PubMed ID: 3481541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM; Finegold SM
    Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
    Werner H; Heizmann W; Luft G
    Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.
    Del Bene VE; Carek PJ; Twitty JA; Burkey LJ
    Antimicrob Agents Chemother; 1985 May; 27(5):817-20. PubMed ID: 3874597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefbuperazone against anaerobic bacteria.
    Wexler H; Carter WT; Harris BH; Finegold SM
    Antimicrob Agents Chemother; 1985 Apr; 27(4):674-6. PubMed ID: 3847274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of 10 antibiotics including pristinamycin and its two components (RP 12536 and 27404) against strict anaerobes].
    Dubreuil L; Houcke I; Singer E
    Pathol Biol (Paris); 1998 Feb; 46(2):147-52. PubMed ID: 9769928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds.
    Wise R; Andrews JM; Hancox J
    Antimicrob Agents Chemother; 1982 Mar; 21(3):486-91. PubMed ID: 6954875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species.
    Byun JH; Kim M; Lee Y; Lee K; Chong Y
    Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.